[Influence of the VEGF antibody targeted vascular therapy on the expression of collagen type I in hyperplastic].
OBJECTIVE
To investigate the influence of the vascular endothelial growth factor( VEGF) antibody targeted vascular therapy on the expression of human collagen type I in hyperplastic scar of nude mice.


METHODS
The hyperplastic scar from one female burn patient with 1% TBSA deep-partial thickness burns were implanted into subcutaneous skin of scapular region of 48 nude mice. Three weeks later, the nude mice were divide into large dose (LA) , medium dose (MD) , small dose (SD) and control groups, with 12 mice in each group. The mice in LA,MD and SD groups were injected with 200 microl of 15,10, 5 microg/ml VEGF monoclonal antibody diluted in 0.01 mol/L PBS, respectively in the scar twice a week for 3 weeks, while those in C group were injected with equal amount of 0. 01 mol/L PBS. The area and volume of the scar in each group were calculated and histological changes were observed, and the expression of collagen type I mRNA and its protein in each group were determined 3 days after treatment.


RESULTS
The volume of scar in LA, MD, SD and C groups were (55.3 +/-4.1, 67.9 +/-5.7, 78.9 +/-5.5, 85.0 +7.3) mm(3), respectively. Compared with that in C group, the volume of the scar were significantly decreased in AD and MD groups ( P <0.05). A few number of vessels and fibroblasts were observed in LD, MD groups, with decreased number of collagen fibers arranged in order. Compared with that in C group ,The expression of procollagen type I mRNA and its protein in C group was obviously higher than those in LD and MD groups ( P < 0. 05) , but it was similar to those in SD group.


CONCLUSIONS
VEGF targeted vascular therapy is beneficial for the inhibition of the angiopoietins of hyperplastic scar, the expression of collagen , and the growth of scar.
Yue
Yi-gang
YG
Department of Plastic Surgery, Affiliated Hospital to Guilin Medical College, Guilin 541001, PR China. y.y.g@263.net
Jiang
Chang-wen
CW
Li
Pei-ying
PY
Zhou
Si
S
D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017439:Cicatrix, Hypertrophic / Q000378:metabolism / Q000628:therapy*; D024042:Collagen Type I / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D015870:Gene Expression; D006801:Humans; D006965:Hyperplasia / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*
D000911:Antibodies, Monoclonal; D024042:Collagen Type I; D012333:RNA, Messenger; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A